Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly (NYSE:LLY) announced significant positive results from its Phase 3 monarchE trial for Verzenio, its treatment for HR+, HER2-, node-positive, high-risk early breast cancer. The study demonstrated that two years of Verzenio plus endocrine therapy achieved a statistically significant improvement in overall survival compared to endocrine therapy alone.
The seven-year landmark analysis revealed sustained benefits in both invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS). The safety profile remained consistent with previous reports, with all patients having completed or discontinued the two-year treatment course. These results establish Verzenio as the standard of care for this high-risk breast cancer patient population.
Eli Lilly (NYSE:LLY) announced positive Phase 3 ATTAIN-2 trial results for orforglipron, its investigational oral GLP-1 receptor agonist for obesity and type 2 diabetes treatment. The highest dose (36mg) achieved significant weight loss of 22.9 lbs (10.5%) compared to placebo's 5.1 lbs (2.2%) at 72 weeks.
Key achievements include A1C reductions of 1.3% to 1.8% from a baseline of 8.1%, with 75% of participants reaching A1C ≤6.5%. The drug demonstrated improvements in cardiovascular risk factors and reduced inflammation markers by 50.6%. The safety profile aligned with injectable GLP-1 medicines, with primarily mild-to-moderate gastrointestinal side effects.
Following these successful results, Lilly plans to initiate global regulatory submissions for orforglipron's approval as a once-daily oral treatment.
Eli Lilly (NYSE:LLY) has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company will be represented by Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer, who will participate in a fireside chat at 9:15 a.m. ET.
Investors can access a live audio webcast of the presentation through Lilly's investor website, with a replay available for approximately 90 days following the event.
Eli Lilly (NYSE:LLY) announced its participation in the upcoming Wells Fargo 20th Annual Healthcare Conference on September 5, 2025. Patrik Jonsson, executive vice president and president of Lilly International, will participate in a fireside chat at 9:30 a.m. ET.
Investors can access a live audio webcast through Lilly's investor website, with a replay available for approximately 90 days following the presentation.
Eli Lilly (NYSE:LLY) announced that Anne White, executive vice president and president of Lilly Neuroscience, will retire on December 31, 2025 after 30 years of service. White, who will remain on Lilly's Executive Committee until retirement, led the global launch of Lilly's first Alzheimer's treatment and previously headed Lilly Oncology, where she played a key role in the Loxo Oncology acquisition.
Under White's leadership, the company expanded its neuroscience portfolio across neurodegeneration, pain, substance use disorders, and psychiatry. She contributed to reducing drug development timelines and accelerating new medicine launches. The company has initiated an internal and external search for her successor.
Eli Lilly (NYSE:LLY) reported exceptional Q2 2025 results with revenue surging 38% to $15.56 billion, primarily driven by strong sales of Zepbound and Mounjaro. The company raised its 2025 full-year revenue guidance by $1.5 billion to $60-62 billion.
Q2 2025 EPS increased 92% to $6.29 on a reported basis and 61% to $6.31 on a non-GAAP basis. Key achievements include positive results for orforglipron in obesity treatment, Mounjaro's cardiovascular outcomes in type 2 diabetes, and Jaypirca's superiority versus Imbruvica in CLL/SLL.
The company completed strategic acquisitions of SiteOne Therapeutics and Verve Therapeutics, while expanding manufacturing capacity to meet growing demand. Updated 2025 EPS guidance was raised to $20.85-$22.10 (reported) and $21.75-$23.00 (non-GAAP).
Eli Lilly (NYSE:LLY) announced positive Phase 3 ATTAIN-1 trial results for orforglipron, its investigational oral GLP-1 receptor agonist, in treating obesity. The once-daily pill demonstrated significant weight loss, with participants taking the highest dose (36mg) losing an average of 27.3 lbs (12.4%) compared to 2.2 lbs (0.9%) with placebo over 72 weeks.
The trial, involving 3,127 adults, met all primary and secondary endpoints. At the highest dose, 59.6% of participants lost ≥10% body weight, and 39.6% lost ≥15%. The drug also showed improvements in cardiovascular risk markers, including a 47.7% reduction in hsCRP levels. The safety profile aligned with injectable GLP-1 therapies, with mainly gastrointestinal side effects.
Lilly plans to submit orforglipron for regulatory review by year-end and is preparing for a global launch.
Eli Lilly (NYSE:LLY) announced groundbreaking results from SURPASS-CVOT, a landmark head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide) to Trulicity (dulaglutide) in type 2 diabetes patients with cardiovascular disease. The trial, involving over 13,000 participants across 30 countries, demonstrated Mounjaro's cardiovascular protection with an 8% lower rate of major adverse cardiovascular events compared to Trulicity.
Key findings include a 16% reduction in all-cause mortality, superior A1C and weight reductions, and enhanced kidney protection with Mounjaro. The drug showed a 28% reduction in MACE-3 events and 39% reduction in all-cause mortality compared to placebo in indirect comparison analyses. The safety profile remained consistent with previous studies, with 13.3% discontinuation rate due to adverse events.
Eli Lilly (NYSE:LLY) announced positive long-term results from the TRAILBLAZER-ALZ 2 extension study for Kisunla (donanemab-azbt) in early symptomatic Alzheimer's disease. The Phase 3 study demonstrated that the drug's benefits continued to grow over three years compared to an untreated control group.
Key findings include: cognitive decline reduction of -0.6 at 18 months and -1.2 at 36 months on the CDR-SB scale, 27% reduced risk of disease progression with earlier treatment, and over 75% of participants achieving amyloid clearance within 76 weeks. The study also confirmed Kisunla's established safety profile with no new safety signals observed over the three-year period.
Eli Lilly (NYSE:LLY) announced positive Phase 3 trial results for Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The BRUIN CLL-314 trial, comparing Jaypirca to Imbruvica (ibrutinib), met its primary endpoint of non-inferiority in overall response rate (ORR), with data favoring Jaypirca (p<0.05).
The groundbreaking study is the first head-to-head Phase 3 trial versus ibrutinib in CLL to include treatment-naïve patients, with this subgroup (n=225) showing particularly strong progression-free survival trends favoring pirtobrutinib. While progression-free survival (PFS) data is not yet mature, early trends favor Jaypirca with no detriment to overall survival.
These results will support future regulatory submissions alongside the upcoming BRUIN CLL-313 Phase 3 study results expected later in 2025.